Therapeutic targeting of CD39 скачать в хорошем качестве

Therapeutic targeting of CD39

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, describes the rationale behind CD39 antagonism as an immunotherapy for multiple cancers. CD39 is a rate-limiting enzyme in the conversion of ATP to immunomodulatory adenosine. It is thought that CD39 antagonism can prevent the accumulation of adenosine and stabilize pro-inflammatory extracellular ATP to restore antitumor immunity. CD39 will likely serve as a synergistic immunotherapy in combination with immune checkpoint blockade via PD-1 inhibition with pembrolizumab or nivolumab among others. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.